Germany - OHE

We found for

How Have HTA Agencies Evolved Their Methods Over Time?

Read more

The Socio-Economic Value of Adult Immunisation Programmes banner

News
April 2024

Adult vaccination programmes deliver socio-economic benefits up to 19 times initial investment, according to new report

Are Recommendations for HTA of Gene Therapies Being Achieved?

Read more

Learnings from the Assessments of Entrectinib and Larotrectinib: Health Technology Assessment Challenges Associated with Tumour-Agnostic Therapies

Read more

© WellcomeCollection

Bridging the Gap: Pathways for Regulatory and Health Technology Assessment of Histology Independent Therapies

Read more

HTA and Payment Mechanisms for New Drugs to Tackle AMR

Read more

The Debate on Indication-Based Pricing in the U.S. and Five Major European Countries

Read more

Market Access

Comparing Access to Orphan Medicinal Products (OMPs) in the United Kingdom and other European countries

Read more

Health Policy and Regulation

Access Mechanisms for Orphan Drugs: A Comparative Study of Selected European Countries

Read more

New Guidelines for Economic Evaluation in Germany and the United Kingdom: Are We Any Closer to Developing International Standards?

Read more

The Life Cycle of Pharmaceuticals: A Cross-National Perspective

Read more

The Road to Sustainability in the UK and German Biotechnology Industries

Read more

Prices, Competition and Regulation in Pharmaceuticals: A Cross-National Comparison

Read more

Risk Adjusting Health Care Resource Allocations

Read more

Managed Care – An Option for the German Health Care System?

Read more

Pharmaceuticals in seven nations

Read more